CABA
Cabaletta Bio, Inc. NASDAQ Listed Oct 25, 2019$2.98
-1.19%
vs $3.02
Mkt Cap $486.6M
52w Low $1.26
58.0% of range
52w High $4.23
50d MA $3.35
200d MA $2.77
P/E (TTM)
—
EV/EBITDA
—
P/B
2.7x
Debt/Equity
0.2x
ROE
-149.8%
P/FCF
-2.3x
RSI (14)
21.10
ATR (14)
$0.24
Beta
3.29
50d MA
$3.35
200d MA
$2.77
Avg Volume
4.2M
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
2929 Arch Street · Philadelphia, PA 19104 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14, 2026 | BMO | -0.41 | -0.39 | +4.9% | 3.59 | -1.1% | +0.6% | -8.3% | -0.6% | -0.6% | +5.2% | — |
| Mar 23, 2026 | BMO | -0.45 | -0.40 | +11.1% | 2.82 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% | — |
| Nov 10, 2025 | BMO | -0.49 | -0.44 | +10.2% | 2.43 | +0.8% | +1.6% | -0.8% | -4.5% | -1.3% | +3.5% | — |
| Aug 7, 2025 | BMO | -0.71 | -0.73 | -2.8% | 1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% | — |
| May 15, 2025 | BMO | -0.67 | -0.71 | -6.0% | 1.81 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% | — |
| Mar 31, 2025 | BMO | -0.65 | -0.65 | +0.0% | 1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% | — |
| Nov 14, 2024 | BMO | -0.59 | -0.62 | -5.1% | 3.78 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% | — |
| Aug 8, 2024 | BMO | -0.55 | -0.56 | -1.8% | 4.01 | +0.7% | +3.7% | +5.3% | +4.1% | -3.9% | +1.8% | — |
| May 15, 2024 | BMO | -0.48 | -0.51 | -6.2% | 12.69 | -1.3% | -0.6% | -2.1% | +4.3% | -5.4% | -3.1% | — |
| Mar 21, 2024 | BMO | -0.39 | -0.46 | -17.9% | 17.54 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% | — |
| Nov 9, 2023 | BMO | -0.39 | -0.37 | +5.1% | 17.52 | +4.2% | +2.1% | -2.6% | +0.3% | -0.6% | +0.4% | — |
| Aug 10, 2023 | BMO | -0.47 | -0.37 | +21.3% | 12.27 | +2.2% | +11.0% | -1.4% | +1.8% | -4.2% | -6.9% | — |
| May 11, 2023 | AMC | -0.48 | -0.45 | +6.2% | 13.12 | -0.1% | -4.7% | -8.2% | +14.6% | -7.8% | +1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | Guggenheim | Maintains | Buy → Buy | — | $2.82 | $2.76 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% |
| Mar 24 | Morgan Stanley | Maintains | Overweight → Overweight | — | $2.82 | $2.76 | -2.1% | -5.3% | +4.1% | +1.4% | -5.0% | -7.8% |
| Oct 31 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.47 | $2.61 | +5.7% | +46.2% | -16.6% | -10.3% | -3.3% | -5.0% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.85 | $3.15 | +10.5% | -18.6% | +7.3% | +16.1% | +0.3% | -0.7% |
| Sep 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.54 | $1.57 | +1.9% | +10.4% | -1.2% | -2.4% | +6.1% | +4.0% |
| Aug 14 | Citigroup | Maintains | Buy → Buy | — | $1.71 | $1.67 | -2.3% | -3.5% | +3.6% | +3.5% | -8.5% | -2.5% |
| Aug 8 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.45 | $1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% |
| Aug 8 | Guggenheim | Maintains | Buy → Buy | — | $1.45 | $1.45 | +0.0% | -6.2% | -2.2% | +0.0% | +28.6% | -3.5% |
| Jun 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.35 | $2.03 | -13.6% | -25.5% | +2.9% | +10.6% | -2.5% | -3.6% |
| May 16 | Guggenheim | Maintains | Buy → Buy | — | $1.81 | $2.14 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% |
| May 16 | Citigroup | Maintains | Buy → Buy | — | $1.81 | $2.14 | +18.2% | +12.2% | -5.4% | -2.1% | -4.3% | -1.1% |
| May 15 | Guggenheim | Maintains | Buy → Buy | — | $1.30 | $1.40 | +7.7% | +39.2% | +12.2% | -5.4% | -2.1% | -4.3% |
| Apr 1 | Morgan Stanley | Maintains | Overweight → Overweight | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | Guggenheim | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | UBS | Maintains | Buy → Buy | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Apr 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.39 | $1.39 | +0.0% | -15.8% | +6.0% | -4.0% | -6.7% | +3.6% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.71 | $2.74 | +1.1% | -14.0% | -7.7% | -2.8% | -1.4% | -4.9% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.43 | $2.45 | +0.8% | +12.8% | -5.1% | -2.3% | +2.0% | -3.5% |
| Dec 20 | Evercore ISI | Downgrade | Outperform → In Line | — | $2.31 | $2.27 | -1.7% | +3.0% | -0.8% | -0.8% | +6.4% | -8.0% |
| Dec 19 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $2.29 | $2.26 | -1.3% | +0.9% | +3.0% | -0.8% | -0.8% | +6.4% |
| Nov 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.03 | $3.00 | -1.0% | -10.9% | -5.9% | -11.0% | -17.3% | +0.0% |
| Nov 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $3.78 | $3.84 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.78 | $3.84 | +1.6% | -19.8% | -10.9% | -5.9% | -11.0% | -17.3% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $4.00 | +1.5% | +6.3% | +6.9% | +4.9% | +0.0% | -7.0% |
| Aug 12 | Evercore ISI | Maintains | Outperform → Outperform | — | $4.16 | $4.26 | +2.4% | +5.3% | +4.1% | -3.9% | +1.8% | +1.8% |
| Aug 12 | Wells Fargo | Maintains | Overweight → Overweight | — | $4.16 | $4.26 | +2.4% | +5.3% | +4.1% | -3.9% | +1.8% | +1.8% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.01 | $4.04 | +0.7% | +3.7% | +5.3% | +4.1% | -3.9% | +1.8% |
| Jun 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.33 | $8.50 | +2.0% | +1.8% | -1.5% | -13.4% | +0.4% | +1.1% |
| Jun 17 | Stifel | Maintains | Buy → Buy | — | $10.66 | $10.54 | -1.1% | -12.2% | -10.8% | -0.2% | +1.8% | -1.5% |
| Jun 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.56 | $13.35 | +6.3% | -15.1% | -12.2% | -10.8% | -0.2% | +1.8% |
| May 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.21 | $11.30 | +0.8% | -2.6% | -2.3% | -5.8% | -1.2% | +2.6% |
| May 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.69 | $12.52 | -1.3% | -0.6% | -2.1% | +4.3% | -5.4% | -3.1% |
| Apr 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $16.11 | $15.95 | -1.0% | +5.4% | +6.2% | +4.3% | -5.1% | +0.3% |
| Apr 4 | Citigroup | Maintains | Buy → Buy | — | $16.44 | $16.79 | +2.1% | -2.0% | +5.4% | +6.2% | +4.3% | -5.1% |
| Mar 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Mar 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.54 | $16.91 | -3.6% | -1.1% | -3.2% | +1.0% | +1.1% | -0.5% |
| Nov 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.69 | $13.60 | -0.7% | +1.4% | +15.6% | -0.2% | +0.2% | -2.7% |
| Nov 29 | Morgan Stanley | Maintains | Overweight → Overweight | — | $13.69 | $13.60 | -0.7% | +1.4% | +15.6% | -0.2% | +0.2% | -2.7% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $17.47 | $18.02 | +3.1% | -0.6% | +0.4% | +3.0% | -0.1% | -1.8% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.52 | $18.25 | +4.2% | +2.1% | -2.6% | +0.3% | -0.6% | +0.4% |
| Nov 8 | Morgan Stanley | Maintains | Overweight → Overweight | — | $16.09 | $16.47 | +2.4% | +6.8% | +1.9% | +2.1% | -2.6% | +0.3% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.80 | $14.58 | -1.5% | -0.2% | -2.4% | +8.3% | +5.7% | +0.0% |
| Sep 18 | Wells Fargo | Maintains | Overweight → Overweight | — | $15.81 | $16.17 | +2.3% | +18.0% | -6.9% | -7.7% | +0.1% | -1.4% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $13.62 | $13.66 | +0.3% | -1.4% | +1.8% | -4.2% | -6.9% | +3.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.27 | $12.54 | +2.2% | +11.0% | -1.4% | +1.8% | -4.2% | -6.9% |
| May 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.16 | $13.10 | -0.5% | -7.8% | +1.4% | -5.4% | -3.0% | -4.6% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.12 | $13.11 | -0.1% | -4.7% | -8.2% | +14.6% | -7.8% | +1.4% |
| May 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.58 | $11.45 | -1.1% | +5.7% | -0.2% | +3.0% | -7.0% | +1.6% |
No insider trades available.
8-K · 5.03
! Medium
Cabaletta Bio, Inc. -- 8-K 5.03: Amendment to Articles / Bylaws
Cabaletta Bio changed its fiscal year end, which may affect earnings reporting timing and investor comparisons to prior periods.
Jun 11
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio updated its corporate presentation on June 3, 2026, available on its investor relations website, indicating potential strategic communications or operational developments for shareholders.
Jun 3
8-K · 2.02
!! High
Cabaletta Bio, Inc. -- 8-K 2.02: Earnings Results
May 14
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
May 14
8-K · 2.02
!! High
Cabaletta Bio, Inc. -- 8-K 2.02: Earnings Results
Cabaletta Bio maintains a strong cash position of $117 million as of March 31, 2026, providing runway for clinical development and operations.
May 4
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio will present positive early data from its RESET-PV trial at ASGCT 2026, demonstrating rese-cel efficacy in pemphigus vulgaris patients without requiring chemotherapy preconditioning, potentially simplifying treatment.
May 4
8-K · 8.01
!! High
Cabaletta Bio, Inc. -- 8-K 8.01: Material Event / Announcement
Cabaletta Bio filed a corporate presentation as a material event, likely signaling updates on its pipeline or strategy that investors should review for potential operational or development changes.
Apr 20
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Cabaletta Bio is progressing late-stage cell therapy candidates for autoimmune diseases, suggesting potential near-term catalyst events that could significantly impact valuation if clinical trials succeed.
Mar 23
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Jennison Associates Llc | 8,905,699 | $20M | Added | Dec 2025 |
| 2 | Millennium Management | 5,903,281 | $16M | Added | Mar 2026 |
| 3 | Vanguard Capital Management Llc | 4,028,991 | $11M | New | Mar 2026 |
| 4 | Two Sigma Investments, Lp | 2,497,917 | $7M | Added | Mar 2026 |
| 5 | Morgan Stanley | 2,687,416 | $6M | Reduced | Dec 2025 |
| 6 | Marshall Wace, Llp | 2,179,818 | $6M | Added | Mar 2026 |
| 7 | Renaissance Technologies Llc | 2,036,663 | $5M | Added | Mar 2026 |
| 8 | Qube Research & Technologies Ltd | 1,934,990 | $5M | Added | Mar 2026 |
| 9 | Woodline Partners Lp | 1,250,242 | $3M | — | Mar 2026 |
| 10 | Superstring Capital Management Lp | 1,066,239 | $3M | Reduced | Mar 2026 |
| 11 | Opaleye Management Inc. | 900,000 | $2M | Added | Dec 2025 |
| 12 | Schroder Investment Management Group | 756,637 | $2M | — | Mar 2026 |
| 13 | Ubs Group Ag | 606,664 | $2M | Added | Mar 2026 |
| 14 | Jane Street Group, Llc | 662,149 | $1M | Added | Dec 2025 |
| 15 | Raiffeisen Bank International Ag | 450,000 | $968K | Added | Dec 2025 |
| 16 | Bank Of America Corp /de/ | 269,257 | $724K | — | Mar 2026 |
| 17 | Point72 Asset Management | 246,615 | $663K | Added | Mar 2026 |
| 18 | Northern Trust Corp | 238,442 | $641K | — | Mar 2026 |
| 19 | Invesco Ltd. | 192,383 | $518K | Added | Mar 2026 |
| 20 | D.e. Shaw & Co | 189,412 | $510K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$486.6M
Enterprise Value
$178.1M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.04x
P/B
2.72x
P/S
—
P/FCF
-2.33x
EV/EBITDA
—
Shares Out
102.3M
Financials (TTM)
Revenue
$0
Net Income
-$175.4M
EBITDA
-$171.6M
Free Cash Flow
-$132.3M
Op Cash Flow
-$131.1M
EPS Basic
$-1.64
EPS Diluted
$-1.97
EPS Forward
$-1.56
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$165.1M
Total Liab.
$53.0M
Total Equity
$112.1M
Cash
$133.6M
LT Debt
$2.9M
Book Value/Sh
$1.10
Debt/Equity
0.24x
Current Ratio
2.77
Quick Ratio
2.77
Returns & Growth
ROE
-149.8%
ROA
-101.7%
ROIC
-123.8%
Rev Growth YoY
+0.0%
EPS Growth YoY
+29.9%
Price Returns
2W
+4.7%
1M
+26.4%
3M
+13.9%
6M
+47.1%
12M
+102.1%
Technicals
52W High
$4.23
52W Low
$1.26
50d MA
$3.35
200d MA
$2.77
RSI (14)
21.10
ATR (14)
$0.24
Beta
3.29
Avg Volume
4.2M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$16.33
High
$32.00
Low
$3.00
Median
$14.00
Data updated apr 24, 2026 11:35pm
· Source: financialmodelingprep.com